I’ve written previously (here and here) about the possible connection between autism and vaccines made with aborted fetal cells.

Now, the September issue of the prestigious Journal of Public Health and Epidemiology�has published a study conducted by scientists at Sound Choice Pharmaceutical Institute�that shows an spike�in autism in country after country where vaccines using fetal cells from aborted babies have been�introduced.

The implicated vaccines are�MMR�(measles/mumps/rubella), Varicella (chickenpox), and Hepatitis A.

Using data from the U.S. government, United Kingdom, Denmark, and Western Australia, researchers found a spike in autism around the world after vaccines using animal cells were replaced by�vaccines using aborted fetal cells:

Autistic disorder birth year change points were identified as 1980.9, 1988.4 and 1996 for the US, 1987 for the UK, 1990.4 for Western Australia, and 1987.5 for Denmark. Change points in these countries corresponded to introduction of or increased doses of human fetal cell line-manufactured�vaccines…. This pattern was repeated in the US, UK, Western Australia and Denmark. Thus, rising autistic disorder prevalence is directly related to vaccines�manufactured�utilizing human fetal cells. Increased paternal age and DSM revisions were not related to rising autistic disorder prevalence.

Lead researcher Dr. Theresa Deisher noted something more alarming, “Not only are the human�fetal contaminated vaccines associated with autistic disorder throughout the world, but also with epidemic�childhood leukemia and lymphomas.”

Right to Life of Michigan goes into great detail explaining the origin of the aborted fetal cell vaccine lines. The implicated manufacturers are Barr Labs, GlaxoSmithKline, Merck, and Sanofi Pasteur.

The RTL Michigan�website lists other vaccines using aborted fetal cells and some alternatives. Unfortunately, there are currently no approved alternatives to the MMR, Varicella or�Hepatitis�A vaccines.

CDC and FDA implicated in cover-up

The bombshells don’t stop. From Sound Choice Pharmaceutical Institute’s press release�announcing the publication: